Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The glioma-associated antigen (GAA) peptide-pulsed autologous dendritic cell vaccine is an investigational personalized cellular immunotherapy developed by the UCLA Jonsson Comprehensive Cancer Center in collaboration with the National Cancer Institute. This biologic therapy utilizes a patient's own dendritic cells, which are harvested via leukapheresis and matured ex vivo. These cells are then pulsed with synthetic peptides corresponding to glioma-associated antigens (GAAs) that are frequently overexpressed in malignant gliomas. The vaccine is specifically designed for patients who are HLA-A*0201 positive. Upon administration, the dendritic cells present these antigens to the host immune system to prime and activate a cytotoxic T-lymphocyte (CTL) response against the tumor cells. It has been evaluated in Phase I clinical trials (notably NCT00612001) for the treatment of malignant gliomas, including glioblastoma multiforme.
- Other names
- GAA peptide-pulsed DC vaccineGAA peptide-pulsed dendritic cell vaccineglioma-associated antigen peptide-pulsed dendritic cell vaccine
02
Targets
γδ TCR (T-cell receptor)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine.